5-(二甲基氨基)戊酸 | 89855-60-7

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 5-(二甲基氨基)戊酸
• 中文别名: 5-(二甲氨基)戊酸
• 英文名称: 5-(dimethylamino)pentanoic acid
• 英文别名: 5-Dimethylamino-valeriansaeure；5-(N,N-dimethylamino)valeric acid；5-(N,N-dimethylamino)pentanoic acid；5-Dimethylamino-pentansaeure；δ-(Dimethylamino)valeriansaeure；5-(Dimethylazaniumyl)pentanoate
• CAS: 89855-60-7
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: UYZSNVLEDLCWGU-UHFFFAOYSA-N

物化性质

• 熔点：
  64-65 °C
• 沸点：
  235.5±23.0 °C(Predicted)
• 密度：
  0.994±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-(Dimethylamino)pentanoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-(Dimethylamino)pentanoic acid
CAS number: 89855-60-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H15NO2
Molecular weight: 145.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(二甲基氨基)戊酸 在 氯化亚砜 作用下， 反应 1.5h， 生成
  参考文献：
  名称：

  WO2008/52742

  摘要：

  公开号：
• 作为产物：
  描述：

  delta-戊内酯 在 palladium 10% on activated carbon 、 四丁基溴化铵 、 水 、 氢气 、 三乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 乙酸乙酯 、 丙酮 为溶剂， 反应 132.0h， 生成 5-(二甲基氨基)戊酸
  参考文献：
  名称：

  COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B

  摘要：

  本发明提供了一种用于传递干扰RNA（如siRNA）的组合物和方法，用于在细胞中（如肝细胞）沉默APOB表达。具体来说，核酸-脂质颗粒能够有效地封装核酸，并有效地将封装的核酸传递给体内的细胞，如肝细胞。本发明的组合物非常有效，因此可以在相对较低的剂量下有效地降低APOB的表达。此外，与先前已知的技术相比，本发明的组合物和方法毒性较低，并且提供了更大的治疗指数。

  公开号：

  US20130123339A1

文献信息

• Peptide Dimethylation: Fragmentation Control via Distancing the Dimethylamino Group
  作者：Adam J. McShane、Yuanyuan Shen、Mary Joan Castillo、Xudong Yao

  DOI：10.1007/s13361-014-0951-7

  日期：2014.10.1

  Direct reductive methylation of peptides is a common method for quantitative proteomics. It is an active derivatization technique; with participation of the dimethylamino group, the derivatized peptides preferentially release intense a1 ions. The advantageous generation of a1 ions for quantitative proteomic profiling, however, is not desirable for targeted proteomic quantitation using multiple reaction monitoring mass spectrometry; this mass spectrometric method prefers the derivatizing group to stay with the intact peptide ions and multiple fragments as passive mass tags. This work investigated collisional fragmentation of peptides whose amine groups were derivatized with five linear ω-dimethylamino acids, from 2-(dimethylamino)-acetic acid to 6-(dimethylamino)-hexanoic acid. Tandem mass spectra of the derivatized tryptic peptides revealed different preferential breakdown pathways. Together with energy resolved mass spectrometry, it was found that shutting down the active participation of the terminal dimethylamino group in fragmentation of derivatized peptides is possible. However, it took a separation of five methylene groups between the terminal dimethylamino group and the amide formed upon peptide derivatization. For the first time, the gas-phase fragmentation of peptides derivatized with linear ω-dimethylamino acids of systematically increasing alkyl chain lengths is reported.

  肽的直接还原性甲基化是定量蛋白质组学中的一种常见方法。这是一种活性衍生化技术；通过二甲氨基基团的参与，衍生化的肽优先释放强烈的a1离子。然而，对于使用多反应监测质谱法的靶向蛋白质定量而言，a1离子的有利生成并不理想；这种质谱方法倾向于使衍生基团保持在完整的肽离子和多个片段上作为被动质量标签。本研究调查了氨酰基被五种线性ω-二甲基氨基酸（从2-（二甲基氨基）-乙酸到6-（二甲基氨基）-己酸）衍生化的肽的碰撞碎裂情况。衍生化胰蛋白酶肽的串联质谱揭示了不同的优先断裂途径。结合能量解析质谱，发现有可能关闭衍生化肽碎裂中末端二甲氨基基团的活性参与。然而，这需要在肽衍生化形成的酰胺与末端二甲氨基基团之间存在五个亚甲基的间隔。本文首次报道了衍生化肽随着系统性增加的烷基链长的线性ω-二甲基氨基酸的气相碎裂情况。
• [EN] IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES<br/>[FR] LIPIDES AMINÉS IONISABLES ET NANOPARTICULES LIPIDIQUES
  申请人：INTELLIA THERAPEUTICS INC

  公开号：WO2020219876A1

  公开（公告）日：2020-10-29

  The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The ionizable amine lipids disclosed herein are useful as ionizable lipids in the formulation of lipid nanoparticle-based compositions.

  该披露提供了可离子化的胺脂质及其盐（例如，其药用可接受盐），用于传递生物活性剂，例如将生物活性剂传递到细胞中以制备工程细胞。本公开的可离子化胺脂质在脂质纳米粒子基础组合物的配方中作为可离子化脂质是有用的。
• [EN] LIPID DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE<br/>[FR] ADMINISTRATION LIPIDIQUE D'AGENTS THÉRAPEUTIQUES AU TISSU ADIPEUX
  申请人：ACUITAS THERAPEUTICS INC

  公开号：WO2018191719A1

  公开（公告）日：2018-10-18

  A method of treating a disease mediated by protein expression in adipose tissue by intraperitoneally administering a composition comprising a lipid nanoparticle encapsulating or associated with a therapeutic agent (e.g., a nucleic acid), thereby delivering the therapeutic agent to adipose tissue of the subject and altering protein expression in the adipose tissue is provided herein. A method for delivering a therapeutic agent to adipose tissue of a subject in need thereof is also provided.

  本发明提供了一种治疗由脂肪组织中蛋白质表达介导的疾病的方法，通过腹膜内给药一种包含脂质纳米粒的制剂，该脂质纳米粒封装或与治疗剂（例如，核酸）相关联，从而将治疗剂递送到受试者的脂肪组织并改变脂肪组织中的蛋白质表达。本发明还提供了一种将治疗剂递送到需要治疗的受试者脂肪组织的方法。
• [EN] HYDROXYMETHYL SUBSTITUTED DIHYDROISOXAZOLE DERIVATIVES USEFUL AS ANTIBIOTIC AGENTS<br/>[FR] DERIVES DE DIHYDROISOXAZOLE A SUBSTITUTION HYDROXYMETHYLE POUVANT SERVIR D'AGENTS ANTIBIOTIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2004078753A1

  公开（公告）日：2004-09-16

  Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, (I) R1a is NH(C=W)R5 or (a); W is O or S; R2 and R3 are for example H or F; R1 is for example hydrogen, or halogen; R5 is selected from hydrogen, (2-6C)alkyl (optionally substituted); R6 and R7 are independently selected from hydrogen, and (1-4C)alkyl (optionally substituted); wherein R4 is either a hydroxymethyl substituent on C-4' of the isoxazoline ring; or R4 is a hydroxymethyl substituent on C-5' of the isoxazoline ring and the stereochemistry at C-5' of the isoxazoline ring and at C-5 of the oxazolidinone ring is selected, such that the compound of formula (I) is a single diastereomer; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  公式（I）的化合物，或其药学上可接受的盐，或其体内可水解的酯，（I）中R1a是NH(C=W)R5或（a）；W是O或S；R2和R3例如是H或F；R1例如是氢或卤素；R5从氢，（2-6C）烷基（可选地取代）中选择；R6和R7独立地从氢和（1-4C）烷基（可选地取代）中选择；其中R4是异噁唑环的C-4'上的羟甲基取代基；或R4是异噁唑环的C-5'上的羟甲基取代基，且异噁唑环的C-5'和噁唑烷酮环的C-5的立体化学被选择，使得公式（I）的化合物是单一对映体；它们作为抗菌剂是有用的；并描述了它们的制备方法和含有它们的药物组合物。
• Lipids and compositions for the delivery of therapeutics
  申请人：Manoharan Muthiah

  公开号：US09186325B2

  公开（公告）日：2015-11-17

  The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention formula (I) provides lipids having the following structure XXXIII wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alky lhetro cycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).

  本发明提供了有利用于体内向细胞传递治疗剂的脂质颗粒中的脂质。具体而言，该发明的公式（I）提供了具有以下结构XXXIII的脂质，其中：R1和R2分别独立地为每次出现的情况下，可以是选择性取代的C10-C30烷基，选择性取代的C10-C30烯基，选择性取代的C10-C30炔基，选择性取代的C10-C30酰基，或-连接-配体；R3为H，可以是选择性取代的C1-C10烷基，选择性取代的C2-C10烯基，选择性取代的C2-C10炔基，烷基杂环，烷基磷酸酯，烷基磷硫酸酯，烷基磷二硫酸酯，烷基磷酸酯，烷基胺，羟基烷基，ω-氨基烷基，ω-(取代)氨基烷基，ω-磷酰基烷基，ω-硫代磷酰基烷基，选择性取代的聚乙二醇（PEG，分子量100-40K），选择性取代的mPEG（分子量120-40K），杂环芳基，杂环，或连接-配体；E为C(O)O或OC(O)。